Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Product information and disease descriptionProduct descriptionProduct information

Product comparison

26 evidence topics · 11 sources

Tebentafusp label: IMCgp100-202 efficacy results versus investigator’s choice
OutcomeKIMMTRAK (N=252)Investigator’s choice of pembrolizumab, ipilimumab, or dacarbazine (N=126)
Overall survival, number of deaths (%)“87 (34.5%)”“63 (50%)”
Overall survival, median in months (95% CI)“21.7 (18.6, 28.6)”“16 (9.7, 18.4)”
Progression-free survival, median in months (95% CI), final analysis“3.3 (3, 5)”“2.9 (2.8, 3)”
Objective response rate (95% CI), not formally tested“9.1% (5.9, 13.4)”“4.8% (1.8, 10.1)”
Complete response“1 (0.4%)”“0”
Partial response“22 (8.7%)”“6 (4.8%)”
Comparison, KIMMTRAK versus investigator’s choiceHazard ratio (95% CI)
Overall survival, prespecified interim analysis, stratified by LDH status“0.51 (0.37, 0.71)”
Progression-free survival, final analysis, stratified by LDH status“0.73 (0.58, 0.94)”
Melphalan hepatic delivery system label: boxed warning, general anesthesia, and REMS-certified settings